PD-1/PD-L1 antibodies have gained clinical approval for the treatment of melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), Hodgkin’s lymphoma, urothelial carcinoma, and gastric cancer10. Here, CD274 is linked to non-small cell lung carcinoma.